The abstract is read at the publisher; the summary is JClub's.
PSMA-PET/CT-guided radiotherapy (PSMAgRT) did not improve 5-year failure-free survival overall (66% vs 62%; HR 0.80; p=0.14) in a phase 2 randomized trial.
- Why it matters: PSMA-PET detects more prostate cancer lesions, but whether PSMA-guided treatment intensification improves failure-free outcomes was unknown. This trial addresses that outcome gap in patients planned for standard-of-care radiotherapy.
- What they did: In a two-center, open-label phase 2 randomized trial (253 analyzed; median follow-up 66 months), patients received either SOC radiotherapy or PSMAgRT to all detected sites across four strata. The primary endpoint was failure-free survival from RT completion, incorporating PSA/radiological progression, next-line therapy, or death.
- The result: Failure-free survival was 66% with PSMAgRT versus 62% with controls (one-sided 90% CI upper bound 1.04). Freedom from biochemical progression favored PSMAgRT overall (72% vs 65%; sHR 0.70; p=0.048) and in high-risk (81% vs 66%) and post-RP (80% vs 68%) strata, supporting rationale for PATRON phase 3.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.